Nelson Heidi D
Oregon Evidence-based Practice Center, Department of Medical Informatics and Clinical Epidemiology, and Oregon Health and Science University, Portland 97239, USA.
JAMA. 2004 Apr 7;291(13):1621-5. doi: 10.1001/jama.291.13.1621.
Use of postmenopausal estrogen has changed since the release of the first results from the Women's Health Initiative in 2002. Professional organizations, the US Food and Drug Administration, and the US Preventive Services Task Force have issued new recommendations against use of estrogen and progestin or progesterone for prevention of chronic conditions. This article applies the current state of evidence for postmenopausal estrogen use to management decisions in 2 clinical scenarios initiating therapy in a perimenopausal woman with hot flashes and discontinuing estrogen use in a long-term user.
自2002年妇女健康倡议（Women's Health Initiative）公布首批结果以来，绝经后雌激素的使用情况已发生变化。专业组织、美国食品药品监督管理局（US Food and Drug Administration）以及美国预防服务工作组（US Preventive Services Task Force）已发布新建议，反对使用雌激素加孕激素或单纯孕激素来预防慢性病。本文将绝经后雌激素使用的当前证据状况应用于两种临床场景的管理决策中，即对一名有潮热症状的围绝经期妇女开始进行激素治疗，以及对一名长期使用者停用雌激素。
